¼¿ï´ëÇб³º´¿ø Á¦10ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãß°èÇмú´ëȸ : 2018-10-20±³À°ÀÏÀÚ : 2018-10-20
±³À°Àå¼Ò : ¼¿ï´ëÇб³º´¿ø ÀÇ»ý¸í¿¬±¸¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦
±³À°ÁÖÁ¦ :
Á¦10ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ
´ã´çÀÚ : ÁÖÁöÇö
¿¬¶ôó : 02-2072-0629
À̸ÞÀÏ :
joojihyun0512@gmail.com ±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀοø : 75¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 20ÀÏ 09:30~10:00 µî·Ï ()
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 10:00~10:25 Innate Immunity ÀåÀ±Çõ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 10:25~10:50 T cell Immunity ½Å¿ë¿ø(¼¿ï´ëº´¿ø)
ÈÞ½Ä 10¿ù 20ÀÏ 10:50~11:10 COFFEE BREAK ()
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 11:10~11:35 B Cell Immunity ÀÌÇÑ»ó(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 11:35~12:00 Immune Regulation and Autoimmunity À̼øÅÂ(¼¿ï´ëº´¿ø)
½Ä»ç 10¿ù 20ÀÏ 12:00~13:00 LUNCH ()
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 13:00~13:50 Plexin D1 as a novel autoantibody in patients with neuropathic pain: bench to bedside Ryo Yamasaki(Kyushu University)
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 13:50~14:10 Pathoimmunogenesis of Autoimmune Encephalitis À̼øÅÂ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 14:10~14:30 Autoimmune Encephalitis: Experiences in Japan Shunya Nakane(Kumamoto University)
±³À°½Ã°£ 10¿ù 20ÀÏ 14:30~14:40 Q&A and Discussion ()
ÈÞ½Ä 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 14:40~15:00 COFFEE BREAK ()
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 15:00~15:50 The gAChR autoantibodies in autoimmune autonomic ganglionopathy: An update on diagnosis and treatment Shunya Nakane(Kumamoto University)
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 15:50~16:10 Postural Tachycardia Syndrome: Evidence of Autoimmunity ¹®Àå¼·(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 10¿ù 20ÀÏ ÀÇÇבּ¸Çõ½Å¼¾ÅÍ CMI 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ 16:10~16:30 Orthostatic Hypotension: Etiologies and treatment outcome º¯Á¤ÀÍ(°µ¿°æÈñ´ëº´¿ø)
±³À°½Ã°£ 10¿ù 20ÀÏ 16:30~16:40 Q&A and Discussion ()